238 related articles for article (PubMed ID: 25558789)
21. Molecular pathways: ROS1 fusion proteins in cancer.
Davies KD; Doebele RC
Clin Cancer Res; 2013 Aug; 19(15):4040-5. PubMed ID: 23719267
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
[TBL] [Abstract][Full Text] [Related]
23. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of crizotinib in patients with
Nogami N; Nakamura A; Shiraiwa N; Kikkawa H; Emir B; Wiltshire R; Morise M
Future Oncol; 2023 Dec; 19(37):2453-2463. PubMed ID: 37605861
[TBL] [Abstract][Full Text] [Related]
25. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
[TBL] [Abstract][Full Text] [Related]
26. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.
Peters TL; Chen N; Tyler LC; Le AT; Dimou A; Doebele RC
Thorac Cancer; 2023 Nov; 14(33):3259-3265. PubMed ID: 37727007
[TBL] [Abstract][Full Text] [Related]
27. Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib.
Zhang H; Zhang Z; Yan N; Li X
Front Oncol; 2024; 14():1405683. PubMed ID: 38835380
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Glaser M; Rasokat A; Prang D; Nogova L; Wömpner C; Schmitz J; Bitter E; Terjung I; Eisert A; Fischer R; John F; von Levetzow C; Michels S; Riedel R; Ruge L; Scharpenseel H; Siebolts U; Merkelbach-Bruse S; Buettner R; Brägelmann J; Wolf J; Scheffler M
Lung Cancer; 2023 Oct; 184():107344. PubMed ID: 37579577
[TBL] [Abstract][Full Text] [Related]
29. Entrectinib for
Tanimura M; Kataoka N; Kunimatsu Y; Tsutsumi R; Sato I; Nakano T; Tanimura K; Takeda T
Respirol Case Rep; 2021 Nov; 9(11):e0857. PubMed ID: 34631105
[TBL] [Abstract][Full Text] [Related]
30. Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.
Sawada H; Taniguchi Y; Iizuka S; Ikeda T; Aga M; Hamakawa Y; Miyazaki K; Misumi Y; Agemi Y; Nakamura Y; Maeda K; Shimokawa T; Okamoto H
Case Rep Oncol; 2023; 16(1):1558-1567. PubMed ID: 38089732
[TBL] [Abstract][Full Text] [Related]
31. Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report.
Liu S; Liu X; Wang T; Zeng C; Ren B; Yu X; Xu M; Li W; Qiao Z; You C; Yang Q; Chen M
Front Oncol; 2022; 12():789941. PubMed ID: 35433411
[TBL] [Abstract][Full Text] [Related]
32. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in
Gainor JF; Tseng D; Yoda S; Dagogo-Jack I; Friboulet L; Lin JJ; Hubbeling HG; Dardaei L; Farago AF; Schultz KR; Ferris LA; Piotrowska Z; Hardwick J; Huang D; Mino-Kenudson M; Iafrate AJ; Hata AN; Yeap BY; Shaw AT
JCO Precis Oncol; 2017; 2017():. PubMed ID: 29333528
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
Ou SI; Hagopian GG; Zhang SS; Nagasaka M
J Thorac Oncol; 2024 May; 19(5):706-718. PubMed ID: 38070596
[TBL] [Abstract][Full Text] [Related]
34. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Fan Y; Drilon A; Chiu CH; Loong HHF; Siena S; Krzakowski M; Dziadziuszko R; Zeuner H; Xue C; Krebs MG
Clin Lung Cancer; 2024 Mar; 25(2):e81-e86.e4. PubMed ID: 38245456
[No Abstract] [Full Text] [Related]
35. Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
Lee JB; Nagasaka M
J Thorac Oncol; 2024 Apr; 19(4):525-527. PubMed ID: 38582542
[No Abstract] [Full Text] [Related]
36. Clinical activity of crizotinib in lung adenocarcinoma harboring a
Kinoshita R; Nakao M; Kiyotoshi H; Hayashi S; Sugihara M; Hirata Y; Kuriyama M; Takeda N; Muramatsu H
Oncol Lett; 2023 Dec; 26(6):515. PubMed ID: 37927416
[TBL] [Abstract][Full Text] [Related]
37. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract][Full Text] [Related]
38. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.
Facchinetti F; Friboulet L
Lung Cancer (Auckl); 2019; 10():87-94. PubMed ID: 31572036
[TBL] [Abstract][Full Text] [Related]
39. A Case of ROS1-Fusion Non-Small Cell Lung Cancer with Acquired BRAF Mutation Developing Unusual Skin Metastasis.
Firoz WA; Sen F; Kiuru M; Huang V; Riess JW
Clin Lung Cancer; 2024 Jun; 25(4):380-383. PubMed ID: 38429142
[No Abstract] [Full Text] [Related]
40. Repotrectinib effective in ROS1-fusion-positive NSCLC.
Sidaway P
Nat Rev Clin Oncol; 2024 Mar; 21(3):167. PubMed ID: 38278875
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
